NO20063230L - CRF receptorantagonister og fremgangsmater for fremstilling derav - Google Patents

CRF receptorantagonister og fremgangsmater for fremstilling derav

Info

Publication number
NO20063230L
NO20063230L NO20063230A NO20063230A NO20063230L NO 20063230 L NO20063230 L NO 20063230L NO 20063230 A NO20063230 A NO 20063230A NO 20063230 A NO20063230 A NO 20063230A NO 20063230 L NO20063230 L NO 20063230L
Authority
NO
Norway
Prior art keywords
crf receptor
receptor antagonists
methods
preparation
crf
Prior art date
Application number
NO20063230A
Other languages
English (en)
Inventor
Deborah Slee
Zhiyong Luo
John Edward Tellew
John Williams
Xiaohu Zhang
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20063230L publication Critical patent/NO20063230L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Det beskrives CRF reseptorantagonister som firmer anvendelse ved behandling av et antall forstyrrelser inkludert behandling av forstyrrelser som manifesterer hypersekresjon av CRF i varmblodige dyr, for eksempel slag. CRF reseptorantagonistene har formel (I) inkludert stereoisomerer, prodmgs og farmasøytisk akseptable salter derav, der RI, R2, R3, Y, Ar og Het er som angitt i beskrivelsen. Det beskrives videre preparater irmeholdende en CRF reseptorantagonist i kombinasjon med en farmasøytisk akseptabel bærer, så vel som fremgangsmåter for anvendelse derav.
NO20063230A 2003-12-22 2006-07-11 CRF receptorantagonister og fremgangsmater for fremstilling derav NO20063230L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53203103P 2003-12-22 2003-12-22
PCT/IB2004/004234 WO2005063755A1 (en) 2003-12-22 2004-12-20 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
NO20063230L true NO20063230L (no) 2006-09-12

Family

ID=34738733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063230A NO20063230L (no) 2003-12-22 2006-07-11 CRF receptorantagonister og fremgangsmater for fremstilling derav

Country Status (19)

Country Link
US (1) US7737154B2 (no)
EP (1) EP1697374B1 (no)
JP (1) JP4926720B2 (no)
KR (1) KR20070009537A (no)
CN (1) CN1938309B (no)
AR (1) AR046967A1 (no)
AU (1) AU2004309168B2 (no)
BR (1) BRPI0417943A (no)
CA (1) CA2550948A1 (no)
IL (1) IL176350A0 (no)
IS (1) IS8526A (no)
MA (1) MA29984B1 (no)
MY (1) MY143499A (no)
NO (1) NO20063230L (no)
NZ (1) NZ547990A (no)
RU (1) RU2394035C2 (no)
TW (1) TW200530242A (no)
WO (1) WO2005063755A1 (no)
ZA (1) ZA200604574B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
KR100854679B1 (ko) * 2007-02-03 2008-08-27 김기형 심플 서비스 로케이션 프로토콜 네트워크 시스템 및 이를구성하는 에이전트.
EP2282998B1 (en) * 2008-04-21 2014-09-10 Albemarle Corporation Processes for producing n-alkylpyrazole
EP2531490B1 (en) * 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
JP6359175B2 (ja) * 2014-04-10 2018-07-18 フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド ＰＡＲＰ阻害剤としての４Ｈ‐ピラゾロ［１，５‐α］ベンゾイミダゾール化合物のアナログ
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
CA3187362A1 (en) 2020-07-27 2022-02-03 John Thomas Feutrill Compounds
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168237T3 (es) * 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
CA2291709A1 (en) * 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
IL137019A0 (en) * 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
YU23602A (sh) * 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
CA2446514A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
ATE397609T1 (de) * 2001-06-12 2008-06-15 Glaxo Group Ltd Corticotropinfreisetzungsfaktor antagonisten
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP1583531B1 (en) * 2003-01-16 2007-04-18 SB Pharmco Puerto Rico Inc Heteroaryl-substituted pyrrolo[2, 3- b]pyridine derivatives as crf receptor antagonists
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070293511A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
EP1697374B1 (en) 2012-08-29
AR046967A1 (es) 2006-01-04
CA2550948A1 (en) 2005-07-14
RU2006126675A (ru) 2008-01-27
NZ547990A (en) 2010-04-30
AU2004309168A1 (en) 2005-07-14
US20070287705A1 (en) 2007-12-13
CN1938309B (zh) 2011-11-09
BRPI0417943A (pt) 2007-04-17
RU2394035C2 (ru) 2010-07-10
MY143499A (en) 2011-05-31
WO2005063755A1 (en) 2005-07-14
IS8526A (is) 2006-07-11
AU2004309168B2 (en) 2009-04-23
TW200530242A (en) 2005-09-16
ZA200604574B (en) 2007-11-28
MA29984B1 (fr) 2008-12-01
JP4926720B2 (ja) 2012-05-09
JP2007515472A (ja) 2007-06-14
EP1697374A1 (en) 2006-09-06
KR20070009537A (ko) 2007-01-18
US7737154B2 (en) 2010-06-15
CN1938309A (zh) 2007-03-28
IL176350A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
HRP20080666T3 (en) Cgrp receptor antagonists
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
WO2006044821A8 (en) Crf receptor antagonists and methods relating thereto
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
TW200626599A (en) CRF receptor antagonists and methods relating thereto
NO20070445L (no) Pyrimidinderivater.
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
SG154443A1 (en) Piperidine derivatives as nk1 antagonists
NO20045486L (no) Nye forbindelser og deres anvendelse
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
GEP20074125B (en) Pyrazolopyridines and methods of making and using the same
NO331174B1 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
MXPA05010760A (es) Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
BRPI0417943A (pt) antagonistas de receptor de crf e métodos relacionados para essa finalidade
TW200633984A (en) Amide compounds and activators of thrombopoietin receptor
MX2007007152A (es) Antagonista de naurocinina-1 con anillo en puente.
TW200514785A (en) Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
NO20035148D0 (no) Tri- og tetra-aza-acenaftylenderivater som CRF- reseptorantagonister
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
ATE250058T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application